Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-017925
Filing Date
2023-05-17
Accepted
2023-05-17 14:24:27
Documents
45
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 571029
2 ex31-1.htm EX-31.1 18172
3 ex31-2.htm EX-31.2 18163
4 ex32-1.htm EX-32.1 6482
5 ex32-2.htm EX-32.2 6621
  Complete submission text file 0001493152-23-017925.txt   3027814

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nxen-20230331.xsd EX-101.SCH 25257
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nxen-20230331_cal.xml EX-101.CAL 28610
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nxen-20230331_def.xml EX-101.DEF 97755
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nxen-20230331_lab.xml EX-101.LAB 230441
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nxen-20230331_pre.xml EX-101.PRE 173610
39 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 347621
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 23931175
SIC: 2834 Pharmaceutical Preparations